Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Kylo-04
- Development stage
- Preclinical
- Lead developer
- Kylonova Biopharma
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
Kylo-04 is an investigational small interfering RNA (siRNA) therapeutic developed by Kylonova for the treatment of hyperlipidemia and dyslipidemia. Utilizing Kylonova's proprietary Nano-lipid Particles Delivery Platform (NPDP), Kylo-04 is designed to target and degrade the mRNA of Angiopoietin-like protein 3 (ANGPTL3) in the liver. ANGPTL3 is a critical regulator of lipid metabolism that inhibits lipoprotein lipase (LPL) and endothelial lipase (EL). By silencing the expression of the ANGPTL3 protein, Kylo-04 facilitates the breakdown of triglycerides and the clearance of cholesterol-rich lipoproteins from the bloodstream. This mechanism aims to provide a potent and long-acting therapeutic option for patients with refractory hypercholesterolemia or familial hyperchylomicronemia who are inadequately controlled by standard lipid-lowering therapies.
- Other names
- Kylo-04-KylonovaKylo04-KylonovaKylo 04-Kylonova
02
Targets
ANGPTL3 (Angiopoietin-like protein 3)
Beyond the preview
Go deeper on Kylo-04.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kylo-04.